Does the media prefer CYRX or ALMR?

In the previous week, Alamar Biosciences had 4 more articles in the media than CryoPort. MarketBeat recorded 8 mentions for Alamar Biosciences and 4 mentions for CryoPort. CryoPort's average media sentiment score of 0.53 beat Alamar Biosciences' score of 0.41 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to CYRX or MRVI?

In the previous week, CryoPort and CryoPort both had 4 articles in the media. Maravai LifeSciences' average media sentiment score of 0.65 beat CryoPort's score of 0.53 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, FTRE or CYRX?

CryoPort has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fortrea $2.72B 0.73 -$986.20M -$0.91 N/A CryoPort $176.18M 4.84 $78.30M -$0.90 N/A

Is FTRE or CYRX more profitable?

Fortrea has a net margin of -3.18% compared to CryoPort's net margin of -20.05%. Fortrea's return on equity of 10.72% beat CryoPort's return on equity. Company Net Margins Return on Equity Return on Assets Fortrea -3.18% 10.72% 2.17% CryoPort -20.05% -7.20% -4.30%

Does the media favor FTRE or CYRX?

In the previous week, Fortrea had 3 more articles in the media than CryoPort. MarketBeat recorded 7 mentions for Fortrea and 4 mentions for CryoPort. CryoPort's average media sentiment score of 0.53 beat Fortrea's score of 0.36 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CYRX or BLFS?

In the previous week, BioLife Solutions had 1 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for BioLife Solutions and 4 mentions for CryoPort. BioLife Solutions' average media sentiment score of 0.78 beat CryoPort's score of 0.53 indicating that BioLife Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLife Solutions 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, CYRX or AZTA?

CryoPort has higher earnings, but lower revenue than Azenta. CryoPort is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $176.18M 4.84 $78.30M -$0.90 N/A Azenta $613.81M 2.70 -$55.76M -$2.76 N/A

Is CYRX or AZTA more profitable?

CryoPort has a net margin of -20.05% compared to Azenta's net margin of -20.63%. Azenta's return on equity of 1.18% beat CryoPort's return on equity. Company Net Margins Return on Equity Return on Assets CryoPort -20.05% -7.20% -4.30% Azenta -20.63% 1.18% 0.97%

Does the media refer more to CYRX or AZTA?

In the previous week, Azenta had 7 more articles in the media than CryoPort. MarketBeat recorded 11 mentions for Azenta and 4 mentions for CryoPort. CryoPort's average media sentiment score of 0.53 beat Azenta's score of 0.33 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Azenta 1 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CryoPort (CYRX) Competitors

$16.95 +0.11 (+0.65%)

Closing price 04:00 PM Eastern

Extended Trading

$16.95 0.00 (0.00%)

As of 07:30 PM Eastern

Compare

CYRX vs. ALMR, MRVI, FTRE, BLFS, and AZTA

Should you buy CryoPort stock or one of its competitors? CryoPort's main competitors and comparable companies include Alamar Biosciences (ALMR), Maravai LifeSciences (MRVI), Fortrea (FTRE), BioLife Solutions (BLFS), and Azenta (AZTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does CryoPort compare to Alamar Biosciences?

CryoPort (NASDAQ:CYRX) and Alamar Biosciences (NASDAQ:ALMR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Alamar Biosciences has a net margin of 0.00% compared to CryoPort's net margin of -20.05%. Alamar Biosciences' return on equity of 0.00% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
Alamar Biosciences	N/A	N/A	N/A

In the previous week, Alamar Biosciences had 4 more articles in the media than CryoPort. MarketBeat recorded 8 mentions for Alamar Biosciences and 4 mentions for CryoPort. CryoPort's average media sentiment score of 0.53 beat Alamar Biosciences' score of 0.41 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

92.9% of CryoPort shares are held by institutional investors. 9.5% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CryoPort has higher revenue and earnings than Alamar Biosciences. CryoPort is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.84	$78.30M	-$0.90	N/A
Alamar Biosciences	$74.21M	22.67	-$29.82M	-$1.96	N/A

CryoPort currently has a consensus target price of $18.38, indicating a potential upside of 9.12%. Alamar Biosciences has a consensus target price of $31.80, indicating a potential upside of 31.19%. Given Alamar Biosciences' higher probable upside, analysts plainly believe Alamar Biosciences is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Alamar Biosciences	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

CryoPort beats Alamar Biosciences on 8 of the 15 factors compared between the two stocks.

How does CryoPort compare to Maravai LifeSciences?

CryoPort (NASDAQ:CYRX) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

CryoPort has higher earnings, but lower revenue than Maravai LifeSciences. CryoPort is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.84	$78.30M	-$0.90	N/A
Maravai LifeSciences	$185.74M	9.87	-$130.77M	-$0.52	N/A

CryoPort has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

CryoPort has a net margin of -20.05% compared to Maravai LifeSciences' net margin of -37.07%. CryoPort's return on equity of -7.20% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

CryoPort presently has a consensus price target of $18.38, indicating a potential upside of 9.12%. Maravai LifeSciences has a consensus price target of $7.38, indicating a potential upside of 4.46%. Given CryoPort's stronger consensus rating and higher probable upside, equities research analysts clearly believe CryoPort is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, CryoPort and CryoPort both had 4 articles in the media. Maravai LifeSciences' average media sentiment score of 0.65 beat CryoPort's score of 0.53 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of CryoPort shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 9.5% of CryoPort shares are held by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

CryoPort beats Maravai LifeSciences on 10 of the 16 factors compared between the two stocks.

How does CryoPort compare to Fortrea?

Fortrea (NASDAQ:FTRE) and CryoPort (NASDAQ:CYRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

In the previous week, Fortrea had 3 more articles in the media than CryoPort. MarketBeat recorded 7 mentions for Fortrea and 4 mentions for CryoPort. CryoPort's average media sentiment score of 0.53 beat Fortrea's score of 0.36 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of CryoPort shares are held by institutional investors. 0.7% of Fortrea shares are held by company insiders. Comparatively, 9.5% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Fortrea has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market.

Fortrea currently has a consensus price target of $22.10, suggesting a potential upside of 5.24%. CryoPort has a consensus price target of $18.38, suggesting a potential upside of 9.12%. Given CryoPort's stronger consensus rating and higher probable upside, analysts plainly believe CryoPort is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

CryoPort has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.72B	0.73	-$986.20M	-$0.91	N/A
CryoPort	$176.18M	4.84	$78.30M	-$0.90	N/A

Fortrea has a net margin of -3.18% compared to CryoPort's net margin of -20.05%. Fortrea's return on equity of 10.72% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
CryoPort	-20.05%	-7.20%	-4.30%

Summary

CryoPort beats Fortrea on 11 of the 16 factors compared between the two stocks.

How does CryoPort compare to BioLife Solutions?

CryoPort (NASDAQ:CYRX) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

In the previous week, BioLife Solutions had 1 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for BioLife Solutions and 4 mentions for CryoPort. BioLife Solutions' average media sentiment score of 0.78 beat CryoPort's score of 0.53 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLife Solutions	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of CryoPort shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 9.5% of CryoPort shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CryoPort has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market.

CryoPort currently has a consensus target price of $18.38, indicating a potential upside of 9.12%. BioLife Solutions has a consensus target price of $31.38, indicating a potential downside of 18.74%. Given CryoPort's stronger consensus rating and higher possible upside, research analysts plainly believe CryoPort is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
BioLife Solutions	0 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.09

CryoPort has higher revenue and earnings than BioLife Solutions. CryoPort is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.84	$78.30M	-$0.90	N/A
BioLife Solutions	$106.69M	17.71	-$4.59M	$1.16	33.28

BioLife Solutions has a net margin of 53.29% compared to CryoPort's net margin of -20.05%. BioLife Solutions' return on equity of 2.70% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
BioLife Solutions	53.29%	2.70%	2.49%

Summary

BioLife Solutions beats CryoPort on 9 of the 16 factors compared between the two stocks.

How does CryoPort compare to Azenta?

CryoPort (NASDAQ:CYRX) and Azenta (NASDAQ:AZTA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 99.1% of Azenta shares are owned by institutional investors. 9.5% of CryoPort shares are owned by company insiders. Comparatively, 10.9% of Azenta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CryoPort has a net margin of -20.05% compared to Azenta's net margin of -20.63%. Azenta's return on equity of 1.18% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
Azenta	-20.63%	1.18%	0.97%

In the previous week, Azenta had 7 more articles in the media than CryoPort. MarketBeat recorded 11 mentions for Azenta and 4 mentions for CryoPort. CryoPort's average media sentiment score of 0.53 beat Azenta's score of 0.33 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Azenta	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CryoPort has higher earnings, but lower revenue than Azenta. CryoPort is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.84	$78.30M	-$0.90	N/A
Azenta	$613.81M	2.70	-$55.76M	-$2.76	N/A

CryoPort has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market. Comparatively, Azenta has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

CryoPort presently has a consensus price target of $18.38, suggesting a potential upside of 9.12%. Azenta has a consensus price target of $41.20, suggesting a potential upside of 9.08%. Given CryoPort's stronger consensus rating and higher possible upside, analysts plainly believe CryoPort is more favorable than Azenta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

CryoPort beats Azenta on 9 of the 16 factors compared between the two stocks.

Get CryoPort News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYRX vs. The Competition

Export

Metric	CryoPort	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$852.93M	$10.59B	$7.15B	$13.16B
Dividend Yield	N/A	1.45%	2.52%	20.73%
P/E Ratio	-18.83	32.45	275.97	25.79
Price / Sales	4.87	105.29	615.58	101.51
Price / Cash	N/A	27.28	27.30	36.12
Price / Book	1.84	6.14	10.68	6.03
Net Income	$78.30M	$56.67B	$3.50B	$380.34M
7 Day Performance	-4.78%	-3.00%	-3.18%	-3.04%
1 Month Performance	9.00%	5.41%	-6.61%	-5.16%
1 Year Performance	80.32%	25.91%	3.69%	-2.48%

CryoPort Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYRX CryoPort	3.2318 of 5 stars	$16.95 +0.7%	$19.33 +14.1%	+81.1%	$852.93M	$176.18M	N/A	738	Analyst Forecast
ALMR Alamar Biosciences	3.3934 of 5 stars	$27.77 -13.9%	$31.80 +14.5%	N/A	$2.24B	$74.21M	N/A	222	Lockup Expiration
MRVI Maravai LifeSciences	1.6384 of 5 stars	$7.43 -5.4%	$7.38 -0.7%	+121.3%	$2.04B	$185.74M	N/A	415
FTRE Fortrea	2.6714 of 5 stars	$20.56 -1.1%	$22.10 +7.5%	+116.9%	$1.98B	$2.72B	N/A	14,300	Analyst Upgrade
BLFS BioLife Solutions	1.873 of 5 stars	$38.61 flat	$31.38 -18.7%	N/A	$1.89B	$96.21M	33.28	155

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYRX) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CryoPort (CYRX) Competitors

CYRX vs. ALMR, MRVI, FTRE, BLFS, and AZTA

How does CryoPort compare to Alamar Biosciences?

Summary

How does CryoPort compare to Maravai LifeSciences?

Summary

How does CryoPort compare to Fortrea?

Summary

How does CryoPort compare to BioLife Solutions?

Summary

How does CryoPort compare to Azenta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX vs. The Competition

CryoPort Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CryoPort (CYRX) Competitors

CYRX vs. ALMR, MRVI, FTRE, BLFS, and AZTA

How does CryoPort compare to Alamar Biosciences?

Is CYRX or ALMR more profitable?

Does the media prefer CYRX or ALMR?

Do insiders and institutionals believe in CYRX or ALMR?

Which has stronger valuation and earnings, CYRX or ALMR?

Do analysts rate CYRX or ALMR?

Summary

How does CryoPort compare to Maravai LifeSciences?

Which has better earnings & valuation, CYRX or MRVI?

Which has more volatility & risk, CYRX or MRVI?

Is CYRX or MRVI more profitable?

Do analysts rate CYRX or MRVI?

Does the media refer more to CYRX or MRVI?

Do institutionals & insiders believe in CYRX or MRVI?

Summary

How does CryoPort compare to Fortrea?

Does the media favor FTRE or CYRX?

Do insiders & institutionals have more ownership in FTRE or CYRX?

Which has more volatility and risk, FTRE or CYRX?

Do analysts prefer FTRE or CYRX?

Which has better earnings & valuation, FTRE or CYRX?

Is FTRE or CYRX more profitable?

Summary

How does CryoPort compare to BioLife Solutions?

Does the media refer more to CYRX or BLFS?

Do institutionals and insiders believe in CYRX or BLFS?

Which has more risk and volatility, CYRX or BLFS?

Do analysts rate CYRX or BLFS?

Which has higher valuation & earnings, CYRX or BLFS?

Is CYRX or BLFS more profitable?

Summary

How does CryoPort compare to Azenta?

Do institutionals & insiders hold more shares of CYRX or AZTA?

Is CYRX or AZTA more profitable?

Does the media refer more to CYRX or AZTA?

Which has stronger valuation & earnings, CYRX or AZTA?

Which has more risk & volatility, CYRX or AZTA?

Do analysts rate CYRX or AZTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX vs. The Competition

CryoPort Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools